| P2093 | author name string | Dawn S Chandler | |
| | Thomas W Bebee | |
| | Jordan T Gladman | |
| P2860 | cites work | Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect | Q39521045 |
| | Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb skeleton | Q40300014 |
| | Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. | Q40741164 |
| | Correlation between severity and SMN protein level in spinal muscular atrophy | Q41102726 |
| | RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN | Q41275236 |
| | The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy | Q43569750 |
| | Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy | Q44329621 |
| | Nestin-CreER mice reveal DNA synthesis by nonapoptotic neurons following cerebral ischemia hypoxia. | Q48295231 |
| | Z/AP, a double reporter for cre-mediated recombination. | Q52178130 |
| | A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy | Q73588971 |
| | The role of the SMN gene in proximal spinal muscular atrophy | Q77293422 |
| | Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy | Q30492560 |
| | CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy | Q30493891 |
| | Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model | Q34030144 |
| | Splicing of the Survival Motor Neuron genes and implications for treatment of SMA | Q34065993 |
| | Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene | Q34152015 |
| | Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy | Q34616822 |
| | Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. | Q35567371 |
| | Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos | Q36578997 |
| | Relationships between stem cell exhaustion, tumour suppression and ageing | Q36611480 |
| | Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells | Q36848828 |
| | A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein | Q36861999 |
| | Spinal muscular atrophy: clinical classification and disease heterogeneity | Q36924707 |
| | Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy | Q37035709 |
| | A mouse model for spinal muscular atrophy | Q38316939 |
| P433 | issue | 12 | |
| P921 | main subject | tamoxifen | Q412178 |
| P304 | page(s) | 927-934 | |
| P577 | publication date | 2011-08-24 | |
| P1433 | published in | Genesis | Q5532784 |
| P1476 | title | Generation of a tamoxifen inducible SMN mouse for temporal SMN replacement | |
| P478 | volume | 49 | |